Antibodies of AGO1


2 antibodies are included.     

 Released    NotSatisfied    Submitted    NotReviewed    OnHold    Submitting    Experimented   
RBP Antibody InfoPrimary-HepG2Secondary-HepG2Primary-K562Secondary-K562Primary-UBERONPrimary-Hela
AGO1Product_ID: RN028PW
Lot_ID: 2
Source: MBLI
Target Name: AGO1-human		 EIF2C1-HEPG2-RN028PW.png<br>Caption: Western blot following shRNA against AGO1/EIF2C1 in HepG2 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.
 K562_MBLI_RN028PW_002_EIF2C1.png<br>Caption: IP-WB characterization of AGO1 specific antibody in K562 cell line . Lane 1 is 2.5% of five million K562 whole cell lysate Input, lane 2 is 2.5% of supernatant after immunoprecipitation and Lane 3 is 50% of IP enrichment using rabbit polyclonal Anti-EIF2C1(AGO1)(Human)pAb. This antibody passes preliminary validation and will be further pursued for primary and secondary validation.
 EIF2C1-k562-RN028PW.png<br>Caption: Western blot following shRNA against EIF2C1 in K562 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.
EIF2C1_Secondary_Western.png<br>Caption: Western blot following shRNA against AGO1 in K562 whole cell lysate using AGO1 specific antibody. Lane 1 is a ladder, lane 2 is K562 non-targeting control knockdown, lane 3 and 4 are two different shRNA against AGO1. AGO1 protein appears as the green arrow, Tubulin serves as a control and appears in red arrow.
AGO1Product_ID: 5053
Lot_ID: 1
Source: Cell Signaling Technology
Target Name: AGO1-human		 AGO1_HepG2.png<br>Caption: IP-Western Blot analysis of HepG2 whole cell lysate using AGO1/EIF2C1 specific antibody. Lane 1 is 3% of ten million whole cell lysate input (lane under '15% input') , lane 2 is 20% of IP enrichment using rabbit normal IgG (lane under 'IgG') and lane 3 is 20% IP enrichment using rabbit monoclonal anti-AGO1/EIF2C11 antibody (lanes under 'anti-AGO1'). Asterisk indicates heavy chain of antibody.
 EIF2C1-HEPG2-FU%27S.png<br>Caption: Western blot following shRNA against EIF2C1 in HepG2 whole cell lysate using EIF2C1 specific antibody. Lane 1 is a ladder, lane 2 is HepG2 non-targeting control knockdown, lane 3 and 4 are two different shRNAs against EIF2C1. EIF2C1 protein appears as the green arrow, GAPDH serves as a control and appears in red arrow.
 AGO1_K562.png<br>Caption: IP-Western Blot analysis of K562 whole cell lysate using AGO1/EIF2C1 specific antibody. Lane 1 is 3% of ten million whole cell lysate input (lane under '15% input') , lane 2 is 20% of IP enrichment using rabbit normal IgG (lane under 'IgG') and lane 3 is 20% IP enrichment using rabbit monoclonal anti-AGO1/EIF2C11 antibody (lanes under 'anti-AGO1'). Asterisk indicates heavy chain of antibody.